

DAFTAR PUSTAKA

1. Bradshaw D, Cashin CH, Kennedy AJ, Roberts NA. Pharmacological and biochemical activities of Tenoxicam (Ro 12-0068), a new non-steroidal anti-inflammatory drug. *Agents Actions*. 1984;15.
2. Todd PA, Clissold SP. Tenoxicam: An Update of its Pharmacology and Therapeutic Efficacy in Rheumatic Diseases. *Drugs Eval*. 1991;41.
3. Syggelos SA, Giannopoulou E, Gouvousis PA, Andonopoulos AP, Aletras AJ, Panagiotopoulos E. In vitro effects of non-steroidal anti-inflammatory drugs on cytokine, prostanoid and matrix metalloproteinase production by interface membranes from loose hip or knee endoprostheses. *Osteoarthr Cartil*. 2007;15.
4. Bolla G, Sanphui P, Nangia A. Solubility advantage of tenoxicam phenolic cocrystals compared to salts. *Cryst Growth Des*. 2013;13.
5. FDA D of H and HS. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Food and Drug Administration. 2017.
6. Olkkola KT, Brunetto A V., Mattila MJ. Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents. *Clin Pharmacokinet*. 1994;26.
7. Patel JR, Carlton RA, Needham TE, Chichester CO, Vogt FG. Preparation, structural analysis, and properties of tenoxicam cocrystals. *Int J Pharm*. 2012;436.
8. Voight R. Buku Pelajaran Teknologi Farmasi ed V, diterjemahkan oleh Soendari Noerono. V. yogyakarta: Universitas Gajah Mada press; 1994.
9. Sathigari S, Chadha G, Lee YHP, Wright N, Parsons DL, Rangari VK, et al. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. *AAPS PharmSciTech*. 2009;10(1).
10. Darwish MK, Foad MM. Enhancement of the dissolution profile of Tenoxicam by a solid dispersion technique and its analytical evaluation using HPLC. *Drug Discov Ther*. 2009;3(1).
11. Larrucea E, Arellano A, Santoyo S, Ygartua P. Study of the complexation behavior of tenoxicam with cyclodextrins in solution: Improved solubility and percutaneous permeability. *Drug Dev Ind Pharm*. 2002;28.
12. Yeh MK, Chang LC, Chiou AHJ. Improving tenoxicam solubility and bioavailability by cosolvent system. *AAPS PharmSciTech*. 2009;10.
13. Shi Q, Moinuddin SM, Cai T. Advances in coamorphous drug delivery systems. *Acta Pharm Sin B*. 2019;9.

14. Wu W, Wang Y, Löbmann K, Grohganz H, Rades T. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems. *Mol Pharm.* 2019;16.
15. Lenz E, Jensen KT, Blaabjerg LI, Knop K, Grohganz H, Löbmann K, et al. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine. *Eur J Pharm Biopharm.* 2015;96.
16. Löbmann K, Grohganz H, Laitinen R, Strachan C, Rades T. Amino acids as co-amorphous stabilizers for poorly water soluble drugs - Part 1: Preparation, stability and dissolution enhancement. *Eur J Pharm Biopharm.* 2013;85.
17. Wang J, Chang R, Zhao Y, Zhang J, Zhang T, Fu Q, et al. Coamorphous Loratadine-Citric Acid System with Enhanced Physical Stability and Bioavailability. *AAPS PharmSciTech.* *AAPS PharmSciTech*; 2017;18.
18. Löbmann K, Laitinen R, Grohganz H, Gordon KC, Strachan C, Rades T. Coamorphous drug systems: Enhanced physical stability and dissolution rate of indomethacin and naproxen. *Mol Pharm.* 2011;8.
19. Zaini E, Fitriani L, Sari RY, Rosaini H, Horikawa A, Uekusa H. Multicomponent Crystal of Mefenamic Acid and N-Methyl-D-Glucamine: Crystal Structures and Dissolution Study. *J Pharm Sci.* 2019;108.
20. Rowe RC. *Handbook of Pharmaceutical Excipients.* sixth ed. Sheskey PJ, Quinn ME, editor. Washington: Pharmaceutical Press and American Pharmacist Association; 2009.
21. Prichard JE. *The British pharmacopoeia.* Vol. 2, British Medical Journal. 2009.
22. Huang Y, Tsai S, Huang C, Wang M, Chen L, Lin C, et al. Intravenous tenoxicam reduces uterine cramps after Cesarean delivery. *Obstet Pediatr Anesth.* 2002;(7):384–7.
23. Vartiainen N, Huang CY, Salminen A, Goldsteins G, Chan PH, Koistinaho J. Piroxicam and NS-398 rescue neurones from hypoxia/reoxygenation damage by a mechanism independent of cyclo-oxygenase inhibition. *J Neurochem.* 2001;76.
24. Sweetman S. *Martindale 36th.* London: Pharmaceutical Press; 2009.
25. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The “High Solubility” Definition of the Current FDA Guidance on Biopharmaceutical Classification System May Be Too Strict for Acidic Drugs. *Pharm Res.* 2004;21(2).
26. Poulin P, Kenne RK, Cornelis, Haddad S. Pharmacokinetics, Pharmacodynamics and Drug Metabolism In Vitro–In Vivo Extrapolation of Clearance: Modeling Hepatic Metabolism Clearance of Highly Bound Drugs and Comparative Assessment with Existing Calculation Methods. *J Pharm Sci.* 2012;101.

27. Convention U. P. The United States Pharmacopeia/National Formulary. In: USPC, editor. USP32/NF27. Maryland; 2014.
28. Yakuji Nippo L. Japanese Pharmacopoeia. 16th ed. Japan; 2011.
29. Di L, Fish P V., Mano T. Bridging solubility between drug discovery and development. *Drug Discov Today*. 2012;17.
30. Sopyan I, N FD, HS I, KY N, TW O, Sarah D. a Review on Solids State of Characterization Method in Pharmaceuticals. *Int Res J Pharm*. 2019;10(1).
31. An JH, Lim C, Kiyonga AN, Chung IH, Lee IK, Mo K, et al. Co-amorphous screening for the solubility enhancement of poorly water-soluble mirabegron and investigation of their intermolecular interactions and dissolution behaviors. *Pharmaceutics*. 2018;10.
32. Chavan RB, Thipparaboina R, Kumar D, Shastri NR. Co amorphous systems: A product development perspective. *Int J Pharm*. 2016;515(1–2):403–15.
33. Rodrigues M, Baptista B, Lopes JA, Sarraguça MC. Pharmaceutical cocrystallization techniques. Advances and challenges. *Int J Pharm*. 2018;547.
34. Hoppu P, Hietala S, Schantz S, Juppo AM. Rheology and molecular mobility of amorphous blends of citric acid and paracetamol. *Eur J Pharm Biopharm*. 2009;71.
35. Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. *Pharm Res*. 2012;29.
36. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharm*. 2012;2012.
37. Sinko P j. *Martin Farmasi Fisika dan Ilmu Farmasetika*. Jakarta: EGC; 2011.
38. Depkes RI. *Farmakope Indonesia edisi V*. Jakarta; 2014.
39. Food and Drug Administration. *Biopharmaceutics Classification System-Based Biowaivers*. M9 ed. 2018.
40. Yasir M, Asif M, Kumar A, Aggarwal A. Biopharmaceutical classification system: An account. *Int J PharmTech Res*. 2010;2.
41. Dressman J, Krämer J. *Pharmaceutical dissolution testing*. Pharmaceutical Dissolution Testing. 2005.
42. Siregar CJ. *Teknologi Farmasi Sediaan Tablet*. Jakarta: EGC; 2010.
43. World Health Organization. *The International Pharmacopoeia*. third ed. Switzerland: WHO publication; 2003.
44. Banakar U. *Pharmaceutical Dissolution Testing*. New York: Marcel Dekker Inc; 1991.

45. Shargel, L & YU ABC. Applied Biopharmaceutics & Pharmacokinetics. Seventh Ed. New York: McGraw-Hill Companies;
46. Bunaciu, A. A, Udriștioiu E gabriela, Aboul-Enein HY. X-Ray Diffraction: Instrumentation and Applications. Crit Rev Anal Chem. 2015;45.
47. Setyawan D, Zaini E. Polimorfisme Bahan Aktif Farmasi. Surabaya: Airlangga University press; 2018.
48. Yadav S, Gupta P, Sharma N, Kumar J. Cocrystals : An alternative Approach to Modify Physicochemical Properties of Drugs. Am J PharmTech Res. 2014;4.
49. Setiabudi A, Hardiann R, Mudzakir A. karakterisasi material;prinsip dan aplikasinya dalam penelitian kimia. UPI Press; 2012.
50. Watson DG. Analisis Farmasi. Hanidita, amalia SF, editor. EGC; 2010.
51. Prof. Dr. Harmita Apt. Analisis Fisikokimia Potensiometri & Sspektroskopi. Depok, Indonesia: EGC; 2015.
52. Behera S. UV-Visible Spectrophotometric Method Development and Validation of Assay of Paracetamol Tablet Formulation. J Anal Bioanal Tech. 2012;3.
53. Prof.Dr.Dachriyanus. Analisis Struktur Senyawa Organik degan Spektroskopi. Padang: LPTIK Universitas Andalas; 2004.
54. Akash MSH, Rehman K. Essential Of Pharmaceutical Analysis. Singapore: Springer; 2018.
55. Friščič T, Jones W. Recent advances in understanding the mechanism of cocrystal formation via grinding. Cryst Growth Des. 2009;9(3):1621–37.
56. El-Gazayerly ON. Characterization and evaluation of tenoxicam coprecipitates. Drug Dev Ind Pharm. 2000;26(9).
57. Topalogu Y, Yelner G, Groning R. Solid Dispersion Of Tenoxicam With Skimmed Milk Via Freeze Drying. Istanbul: Departemen Biopharmaceutic Pharmacokinetics; 1999.
58. Departemen Kesehatan Republik Indonesia. Farmakope Indonesia Edisi V. Jakarta: Departemen Kesehatan RI; 2014.
59. Wairkar S, Gaud R. Co-Amorphous Combination of Nateglinide-Metformin Hydrochloride for Dissolution Enhancement. AAPS PharmSciTech [Internet]. AAPS PharmSciTech; 2016;17(3):673–81. Available from: <http://dx.doi.org/10.1208/s12249-015-0371-4>
60. Singh AK, García PL, Gomes FP, Kedor-Hackmann ERM, Santoro MIRM. Comparative study on two rapid and sensitive methods for quantitative determination of tenoxicam in tablets. Rev Bras Ciencias Farm J Pharm Sci. 2007;43(4):615–22.